|Bid||11.76 x 900|
|Ask||13.99 x 800|
|Day's range||11.53 - 12.38|
|52-week range||5.47 - 13.50|
|Beta (5Y monthly)||0.77|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||24.00|
Concert will present at the Stifel Healthcare Conference and participate in a fireside chat at the Jefferies London Healthcare Conference.
Concert will host a conference call and webcast today at 8:30 a.m. ET to provide an update on the Company and discuss third quarter 2020 results.
Concert initiated THRIVE-AA1, a Phase 3 study to evaluate the efficacy and safety of CTP-543 in adults with moderate to severe alopecia areata.